GammaTile Shows Promise in Newly Diagnosed Glioblastoma
PROVIDENCE, R.I., August 18, 2026 GT Medical Technologies, Inc. announced new clinical findings suggesting that its GammaTile® targeted radiation...
brain cancer
Advertisement
Cerenome Advances CNS Oncology Platform and Trials
Houston, Texas, August 14, 2026 Cerenome, Inc. reported continued progress across its integrated central nervous system (CNS) oncology platform,...
Laminar Completes CLINGLIO Trial Enrollment for LAM561
MALLORCA, Spain, July 23, 2026 Laminar Pharmaceuticals S.A. has announced the successful completion of patient recruitment for the CLINGLIO...
Nuvation Bio Expands Safusidenib Program with Strong Phase II Data
NEW YORK, July 20, 2026 Nuvation Bio Inc. has announced positive updated Phase II clinical data for safusidenib, its...
Northwest Biotherapeutics to Present DCVax-L Survival Analysis at BNOS 2026
BETHESDA, Md., July 2, 2026 Northwest Biotherapeutics announced that its Chief Technical Officer, Dr. Marnix Bosch, will deliver a...
Advertisements
CraniUS Secures NIH Grant for Glioblastoma Therapy
BALTIMORE, June 29, 2026 CraniUS Therapeutics has received an initial $1.1 million award through the National Institutes of Health...
Knoa Pharma and GCAR Expand Glioblastoma Trial Efforts
STAMFORD, Conn., June 24, 2026 Knoa Pharma LLC and the Global Coalition for Adaptive Research (GCAR) announced a significant...
Novocure Reports Phase 3 TRIDENT Trial Results
BAAR, Switzerland | June 18, 2026 Novocure has announced topline results from its Phase 3 TRIDENT trial, which evaluated...
NeOnc Expands International Clinical Development of NEO212 for Glioblastoma
CALABASAS, Calif., June 16, 2026 NeOnc Technologies Holdings, Inc. announced that the Department of Health – Abu Dhabi (DOH)...
Rznomics Highlights Early Clinical Activity of RZ-001 at ASNO 2026
SEONGNAM and SEOUL, South Korea, June 15, 2026 Rznomics Inc., a clinical-stage biopharmaceutical company focused on RNA-based gene therapies,...
Advertisement
